Common aspirin may boost power of leading lung cancer drug
NCT ID NCT04184921
Summary
This study tested whether adding low-dose aspirin to the standard lung cancer drug osimertinib could help patients live longer without their cancer getting worse. It involved 216 adults with advanced, EGFR-positive non-small cell lung cancer who were starting first-line treatment. Researchers wanted to see if aspirin could help overcome the cancer's common resistance to osimertinib, potentially leading to better disease control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER NON-SMALL CELL STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Daping Hospital
Chongqing, Chongqing Municipality, 400000, China
Conditions
Explore the condition pages connected to this study.